Concordance between different amyloid immunoassays and visual amyloid positron emission tomographic assessment.

pROC: an open-source package for R and S+ to analyze and compare ROC curves

Robin, X., Turck, N., Hainard, A., Tiberti, N., Lisacek, F., Sanchez, J.-C., & Müller, M. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-77 · Cited by 13,697 · see citing works

Practical Statistics for Medical Research

Altman, D. G. (1990) · doi:10.1201/9780429258589 · Cited by 10,668 · see citing works

Practical Statistics for Medical Research.

Bartko, J. J., & Altman, D. G. (1992) · Journal of the American Statistical Association · doi:10.2307/2290246 · Cited by 4,834 · see citing works

Comparing correlated correlation coefficients

Meng, X.-L., Rosenthal, R., & Rubin, D. B. (1992) · Psychological Bulletin · doi:10.1037/0033-2909.111.1.172 · Cited by 2,472 · see citing works

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · see citing works

mixtools : An R Package for Analyzing Finite Mixture Models

Benaglia, T., Chauveau, D., Hunter, D. R., & Young, D. S. (2009) · Journal of Statistical Software · doi:10.18637/jss.v032.i06 · Cited by 1,351 · see citing works

Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease

Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Lopresti, B. J., Ziolko, S., Bi, W., Paljug, W. R., et al. (2008) · Brain · doi:10.1093/brain/awn016 · Cited by 933 · see citing works

Cerebrospinal Fluid β-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain

Tapiola, T., Alafuzoff, I., Herukka, S.-K., Parkkinen, L., Hartikainen, P., Soininen, H., & Pirttilä, T. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.596 · Cited by 896 · see citing works

Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study

Clark, C. M., Pontecorvo, M. J., Beach, T. G., Bedell, B. J., Coleman, R. E., Doraiswamy, P. M., Fleisher, A. S., Reiman, E. M., Sabbagh, M. N., Sadowsky, C. H., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70142-4 · Cited by 855 · see citing works

Cerebrospinal Fluid Levels ofβ-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia

Buchhave, P. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.155 · Cited by 664 · see citing works

Cerebrospinal Fluid β-Amyloid(1-42) in Alzheimer Disease: Differences Between Early- and Late-Onset Alzheimer Disease and Stability During the Course of Disease

Andreasen, N., Hesse, C., Davidsson, P., Minthon, L., Wallin, A., Winblad, B., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (1999) · Archives of Neurology · doi:10.1001/archneur.56.6.673 · Cited by 660 · see citing works

CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study

Strozyk, D., Blennow, K., White, L. R., & Launer, L. J. (2003) · Neurology · doi:10.1212/01.wnl.0000046581.81650.d0 · Cited by 604 · see citing works

Amyloid biomarkers in Alzheimer's disease

Blennow, K., Mattsson, N., Schöll, M., Hansson, O., & Zetterberg, H. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.03.002 · Cited by 470 · see citing works

Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People

De Meyer, G. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.179 · Cited by 462 · see citing works

<scp>CSF</scp> A<i>β</i>42/A<i>β</i>40 and A<i>β</i>42/A<i>β</i>38 ratios: better diagnostic markers of Alzheimer disease

Janelidze, S., Zetterberg, H., Mattsson, N., Palmqvist, S., Vanderstichele, H., Lindberg, O., van Westen, D., Stomrud, E., Minthon, L., Blennow, K., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.274 · Cited by 456 · see citing works

Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β‐amyloid

Landau, S. M., Lu, M., Joshi, A. D., Pontecorvo, M., Mintun, M. A., Trojanowski, J. Q., Shaw, L. M., Jagust, W. J., & Initiative, F. T. A. D. N. (2013) · Annals of Neurology · doi:10.1002/ana.23908 · Cited by 401 · see citing works

Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease

Palmqvist, S., Zetterberg, H., Mattsson, N., Johansson, P., Initiative, F. T. A. D. N., Minthon, L., Blennow, K., Olsson, M., For the Swedish BioFINDER study group, Hansson, O., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001991 · Cited by 375 · see citing works

Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β‐amyloid (1–42) in human cerebrospinal fluid

Bittner, T., Zetterberg, H., Teunissen, C. E., Ostlund, R. E., Militello, M., Andreasson, U., Hubeek, I., Gibson, D., Chu, D. C., Eichenlaub, U., et al. (2016) · Alzheimer's &amp; Dementia · doi:10.1016/j.jalz.2015.09.009 · Cited by 374 · see citing works

Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid β-Amyloid 42: A Cross-Validation Study Against Amyloid Positron Emission Tomography

Palmqvist, S., Zetterberg, H., Blennow, K., Vestberg, S., Andreasson, U., Brooks, D. J., Owenius, R., Hägerström, D., Wollmer, P., Minthon, L., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1358 · Cited by 368 · see citing works

Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease

Mattsson, N., Insel, P. S., Donohue, M., Landau, S., Jagust, W. J., Shaw, L. M., Trojanowski, J. Q., Zetterberg, H., Blennow, K., & Weiner, M. W. (2015) · Brain · doi:10.1093/brain/awu367 · Cited by 237 · see citing works

Mass Spectrometry–Based Candidate Reference Measurement Procedure for Quantification of Amyloid-β in Cerebrospinal Fluid

Leinenbach, A., Pannee, J., Dülffer, T., Huber, A., Bittner, T., Andréasson, U., Gobom, J., Zetterberg, H., Kobold, U., Portelius, E., et al. (2014) · Clinical Chemistry · doi:10.1373/clinchem.2013.220392 · Cited by 158 · see citing works

Association Between In Vivo Fluorine 18–Labeled Flutemetamol Amyloid Positron Emission Tomography Imaging and In Vivo Cerebral Cortical Histopathology

Wolk, D. A. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.153 · Cited by 156 · see citing works

Evaluation of CSF Biomarkers as Predictors of Alzheimer's Disease: A Clinical Follow-Up Study of 4.7 Years

Hertze, J., Minthon, L., Zetterberg, H., Vanmechelen, E., Blennow, K., & Hansson, O. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100207 · Cited by 132 · see citing works

Pittsburgh compound B imaging and cerebrospinal fluid amyloid-β in a multicentre European memory clinic study

Leuzy, A., Chiotis, K., Hasselbalch, S. G., Rinne, J. O., de Mendonça, A., Otto, M., Lleó, A., Castelo-Branco, M. S., Santana, I. J., Johansson, J. J., et al. (2016) · Brain · doi:10.1093/brain/aww160 · Cited by 132 · see citing works

Reference measurement procedure for CSF amyloid beta (Aβ)1–42 and the CSF Aβ1–42/Aβ1–40 ratio – a cross‐validation study against amyloid PET

Pannee, J., Portelius, E., Minthon, L., Gobom, J., Andréasson, U., Zetterberg, H., Hansson, O., & Blennow, K. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13838 · Cited by 84 · see citing works

Comparison of Visual and Quantitative Florbetapir F 18 Positron Emission Tomography Analysis in Predicting Mild Cognitive Impairment Outcomes.

Schreiber, S., Landau, S., Fero, A., Schreiber, F., & Jagust, W. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.1633 · Cited by 83 · see citing works

Optimized Standard Operating Procedures for the Analysis of Cerebrospinal Fluid Aβ42 and the Ratios of Aβ Isoforms Using Low Protein Binding Tubes

Vanderstichele, H., Janelidze, S., Demeyer, L., Coart, E., Stoops, E., Herbst, V., Mauroo, K., Brix, B., & Hansson, O. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160286 · Cited by 80 · see citing works

Importance and Impact of Preanalytical Variables on Alzheimer Disease Biomarker Concentrations in Cerebrospinal Fluid

Bastard, N. L., Deyn, P. P. D., & Engelborghs, S. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2014.236679 · Cited by 69 · see citing works

Identification of an important potential confound in CSF AD studies: aliquot volume

Toombs, J., Paterson, R. W., Lunn, M. P., Nicholas, J. M., Fox, N. C., Chapman, M. D., Schott, J. M., & Zetterberg, H. (2013) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2013-0293 · Cited by 43 · see citing works

Development and Advanced Validation of an Optimized Method for the Quantitation of Aβ42 in Human Cerebrospinal Fluid

Cullen, V., Fredenburg, R. A., Evans, C. L., Conliffe, P. R., & Solomon, M. E. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9360-7 · Cited by 39 · see citing works

Diagnostic Values of Cerebrospinal Fluid T-Tau and Aβ42 using Meso Scale Discovery Assays for Alzheimer's Disease

Pan, C., Korff, A., Galasko, D. R., Ginghină, C., Peskind, E. R., Li, G., Quinn, J. F., Montine, T. J., Cain, K. C., Shi, M. Y., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-143099 · Cited by 36 · see citing works

Comparison of Simplified Parametric Methods for Visual Interpretation of 11C-Pittsburgh Compound-B PET Images

Zwan, M. D., Ossenkoppele, R., Tolboom, N., Beunders, A. J. M., Kloet, R. W., Adriaanse, S. M., Boellaard, R., Windhorst, A. D., Raijmakers, P. G. H. M., Adams, H., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.139121 · Cited by 31 · see citing works

Analysis of Cerebrospinal Fluid and [ 11 C]PIB PET Biomarkers for Alzheimer’s Disease with Updated Protocols

Wang, M. J., Yi, S., Han, J.-Y., Park, Y. H., Jang, J., Chun, I. K., Giau, V. V., Bagyinszky, E., Lim, K., Kang, S. M., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160143 · Cited by 26 · see citing works

The impact of Tween 20 on repeatability of amyloid β and tau measurements in cerebrospinal fluid

Toombs, J., Paterson, R. W., Nicholas, J. M., Petzold, A., Schott, J. M., & Zetterberg, H. (2015) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2015-0414 · Cited by 4 · see citing works

P1‐116: Correlation of the modified innotest β‐amyloid 1‐42 with a lc‐ms/ms candidate reference method

Vandijck, M. L. J., Moonen, R., Andréasson, U., Bastard, N. L., Dauwe, M., Blennow, K., & Kostanjevečki, V. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.06.314 · Cited by 2 · see citing works

The Amyloid-β Pathway in Alzheimer’s Disease

Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P., Vendruscolo, M., Iwatsubo, T., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01249-0 · Cited by 1,952 · see citing works

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Hansson, O., Lehmann, S., Otto, M., Zetterberg, H., & Lewczuk, P. (2019) · Alzheimer's Research &amp; Therapy · doi:10.1186/s13195-019-0485-0 · Cited by 585 · see citing works

Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status

Palmqvist, S., Janelidze, S., Stomrud, E., Zetterberg, H., Karl, J., Zink, K., Bittner, T., Mattsson, N., Eichenlaub, U., Blennow, K., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1632 · Cited by 435 · see citing works

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease

Janelidze, S., Stomrud, E., Smith, R., Palmqvist, S., Mattsson, N., Airey, D. C., Proctor, N. K., Chai, X., Shcherbinin, S., Sims, J. R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15436-0 · Cited by 450 · see citing works

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease

Palmqvist, S., Insel, P. S., Stomrud, E., Janelidze, S., Zetterberg, H., Brix, B., Eichenlaub, U., Dage, J. L., Chai, X., Blennow, K., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201911170 · Cited by 353 · see citing works

The complexity of Alzheimer’s disease: an evolving puzzle

Ferrari, C., & Sorbi, S. (2021) · Physiological Reviews · doi:10.1152/physrev.00015.2020 · Cited by 324 · see citing works

Medial temporal lobe connectivity and its associations with cognition in early Alzheimer’s disease

Berron, D., van Westen, D., Ossenkoppele, R., Strandberg, O. T., & Hansson, O. (2020) · Brain · doi:10.1093/brain/awaa068 · Cited by 298 · see citing works

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment

Cicognola, C., Janelidze, S., Hertze, J., Zetterberg, H., Blennow, K., Mattsson, N., & Hansson, O. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00804-9 · Cited by 309 · see citing works

Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease

Shaw, L. M., Arias, J., Blennow, K., Galasko, D., Molinuevo, J. L., Salloway, S., Schindler, S., Carrillo, M. C., Hendrix, J. A., Ross, A., et al. (2018) · Alzheimer's &amp; Dementia · doi:10.1016/j.jalz.2018.07.220 · Cited by 266 · see citing works

Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders

Leuzy, A., Smith, R., Ossenkoppele, R., Santillo, A., Borroni, E., Klein, G., Ohlsson, T., Jögi, J., Palmqvist, S., Mattsson-Carlgren, N., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.0989 · Cited by 222 · see citing works

Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse

Alcolea, D., Pegueroles, J., Muñoz, L., Camacho, V., López‐Mora, D., Fernández‐León, A., Le Bastard, N., Huyck, E., Nadal, A., Olmedo, V., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.50873 · Cited by 183 · see citing works

Predicting clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ(1–42), pTau and tTau CSF immunoassays

Blennow, K., Shaw, L. M. J., Stomrud, E., Mattsson, N., Toledo, J. B., Buck, K., Wahl, S., Eichenlaub, U., Lifke, V., Simon, M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-54204-z · Cited by 193 · see citing works

Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p‐tau

Janelidze, S., Palmqvist, S., Leuzy, A., Stomrud, E., Verberk, I. M. W., Zetterberg, H., Ashton, N. J., Pesini, P., Sarasa, L., Allué, J. A., et al. (2022) · Alzheimer's &amp; Dementia · doi:10.1002/alz.12395 · Cited by 188 · see citing works

An accurate fully automated panel of plasma biomarkers for Alzheimer's disease

Palmqvist, S., Stomrud, E., Cullen, N. C., Janelidze, S., Manuilova, E., Jethwa, A., Bittner, T., Eichenlaub, U., Suridjan, I., Kollmorgen, G., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12751 · Cited by 161 · see citing works

Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer’s disease

Leitão, M. J., Silva‐Spínola, A., Santana, I. J., Olmedo, V., Nadal, A., Bastard, N. L., & Baldeiras, I. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0550-8 · Cited by 164 · see citing works

Cognitive effects of Lewy body pathology in clinically unimpaired individuals

Palmqvist, S., Rossi, M., Hall, S., Quadalti, C., Mattsson, N., Dellavalle, S., Tideman, P., Pereira, J. B., Nilsson, M. H., Mammana, A., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02450-0 · Cited by 155 · see citing works

Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup

Rabinovici, G. D., Knopman, D. S., Arbizu, J., Benzinger, T. L. S., Donohoe, K. J., Hansson, O., Herscovitch, P., Kuo, P. H., Lingler, J. H., Minoshima, S., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14338 · Cited by 151 · see citing works

The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau

Hansson, O., Batrla, R., Brix, B., Carrillo, M. C., Corradini, V., Edelmayer, R. M., Esquivel, R. N., Hall, C., Lawson, J., Bastard, N. L., et al. (2021) · Alzheimer's &amp; Dementia · doi:10.1002/alz.12316 · Cited by 136 · see citing works

Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer’s Disease Diagnosis

Bjerke, M., & Engelborghs, S. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170680 · Cited by 132 · see citing works

Blood-based biomarkers for Alzheimer’s disease—An update

Zetterberg, H. (2018) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2018.10.025 · Cited by 128 · see citing works

The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers

Ashton, N. J., Leuzy, A., Karikari, T. K., Mattsson-Carlgren, N., Dodich, A., Boccardi, M., Corre, J., Drzezga, A., Nordberg, A., Ossenkoppele, R., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05253-y · Cited by 142 · see citing works

Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer’s disease dementia in mild cognitive impairment

Baldeiras, I., Santana, I. J., Leitão, M. J., Gens, H., Pascoal, R., Tábuas‐Pereira, M., Beato-Coelho, J., Duro, D., Almeida, M. R., & Oliveira, C. R. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0362-2 · Cited by 118 · see citing works

Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease

Alawode, D. O. T., Heslegrave, A., Ashton, N. J., Karikari, T. K., Simrén, J., Montoliu‐Gaya, L., Pannee, J., O’Connor, A., Weston, P. S. J., Lantero‐Rodriguez, J., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13332 · Cited by 100 · see citing works

A brief history of “Alzheimer disease”

Knopman, D. S., Petersen, R. C., & Jack, C. R. (2019) · Neurology · doi:10.1212/wnl.0000000000007583 · Cited by 97 · see citing works

Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease

Leuzy, A., Bollack, A., Pellegrino, D., Teunissen, C. E., Joie, R. L., Rabinovici, G. D., Franzmeier, N., Johnson, K. A., Barkhof, F., Shaw, L. M. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14528 · Cited by 97 · see citing works

Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy

Grothe, M. J., Moscoso, A., Ashton, N. J., Karikari, T. K., Lantero‐Rodriguez, J., Snellman, A., Zetterberg, H., Blennow, K., Schöll, M., & Initiative, A. D. N. (2021) · Neurology · doi:10.1212/wnl.0000000000012513 · Cited by 96 · see citing works

MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study

ten Kate, M., Redolfi, A., Peira, E., Bos, I., Vos, S. J., Vandenberghe, R., Gabel, S., Schaeverbeke, J., Scheltens, P., Blin, O., et al. (2018) · Alzheimer's Research &amp; Therapy · doi:10.1186/s13195-018-0428-1 · Cited by 78 · see citing works

Test‐retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models

Cullen, N. C., Janelidze, S., Mattsson, N., Palmqvist, S., Bittner, T., Suridjan, I., Jethwa, A., Kollmorgen, G., Brum, W. S., Zetterberg, H., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12706 · Cited by 84 · see citing works

Diagnostic Biomarkers of Amyloid and Tau Pathology in Alzheimer's Disease: An Overview of Tests for Clinical Practice in the United States and Europe

Iaccarino, L., Burnham, S. C., Dell’Agnello, G., Dowsett, S. A., & Epelbaum, S. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.43 · Cited by 81 · see citing works

Derivation of cutoffs for the Elecsys® amyloid β (1–42) assay in Alzheimer's disease

Shaw, L. M. J., Waligórska, T., Fields, L., Korecka, M., Figurski, M., Trojanowski, J. Q., Eichenlaub, U., Wahl, S., Quan, M., Pontecorvo, M. J., et al. (2018) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.07.002 · Cited by 81 · see citing works

Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup

Rabinovici, G. D., Knopman, D. S., Arbizu, J., Benzinger, T. L. S., Donohoe, K. J., Hansson, O., Herscovitch, P., Kuo, P. H., Lingler, J. H., Minoshima, S., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268756 · Cited by 82 · see citing works

Mass spectrometry‐based methods for robust measurement of Alzheimer's disease biomarkers in biological fluids

Korecka, M., & Shaw, L. M. J. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15465 · Cited by 79 · see citing works

Normalization of CSF pTau measurement by Aβ40 improves its performance as a biomarker of Alzheimer’s disease

Guo, T., Korman, D., Joie, R. L., Shaw, L. M. J., Trojanowski, J. Q., Jagust, W. J., Landau, S. M., & Initiative, A. D. N. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00665-8 · Cited by 66 · see citing works

Comparing CSF amyloid‐beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status

Willemse, E. A. J., Tijms, B. M., van Berckel, B. N. M., Bastard, N. L., van der Flier, W. M., Scheltens, P., & Teunissen, C. E. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12182 · Cited by 62 · see citing works

Cerebrospinal fluid A beta 1–40 peptides increase in Alzheimer’s disease and are highly correlated with phospho-tau in control individuals

Lehmann, S., Dumurgier, J., Ayrignac, X., Marelli, C., Alcolea, D. A., Fortea, J., Thouvenot, É., Delaby, C., Hirtz, C., Vialaret, J., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00696-1 · Cited by 62 · see citing works

Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline

Stockmann, J., Verberk, I. M. W., Timmesfeld, N., Denz, R., Budde, B., Lange-Leifhelm, J., Scheltens, P., van der Flier, W. M., Nabers, A., Teunissen, C. E., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00738-8 · Cited by 62 · see citing works

Alzheimer’s disease biomarkers and their current use in clinical research and practice

Hunter, T., Santos, L. E., Tovar-Moll, F. F., & Felice, F. G. D. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02709-z · Cited by 66 · see citing works

Biofluid‐based biomarkers for Alzheimer's disease–related pathologies: An update and synthesis of the literature

Zetterberg, H. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12618 · Cited by 57 · see citing works

Establishing In-House Cutoffs of CSF Alzheimer’s Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort

Orellana, A., García‐González, P., Valero, S., Montrreal, L., de Rojas, I., Hernández, I., Rosende‐Roca, M., Vargas, L., Tartari, J. P., Antonio, E. E., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23136891 · Cited by 57 · see citing works

Amyloid-driven disruption of default mode network connectivity in cognitively healthy individuals

Ingala, S., Tomassen, J., Collij, L. E., Prent, N., Ent, D. V. ‘., ten Kate, M., Konijnenberg, E., Yaqub, M. M., Scheltens, P., de Geus, E. J. C., et al. (2021) · Brain Communications · doi:10.1093/braincomms/fcab201 · Cited by 59 · see citing works

Alzheimer disease biomarkers: moving from CSF to plasma for reliable detection of amyloid and tau pathology

Kang, J. H., Korecka, M., Lee, E. B., Cousins, K. A. Q., Tropea, T. F., Chen-Plotkin, A. A., Irwin, D. J., Wolk, D., Brylska, M., Wan, Y., et al. (2023) · Clinical Chemistry · doi:10.1093/clinchem/hvad139 · Cited by 64 · see citing works

White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation

Teunissen, C. E., Otto, M., Engelborghs, S., Herukka, S., Lehmann, S., Lewczuk, P., Lleó, A., Perret‐Liaudet, A., Tumani, H., Turner, M. R., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0359-x · Cited by 56 · see citing works

Towards a unified protocol for handling of CSF before β-amyloid measurements

Janelidze, S., Stomrud, E., Brix, B., & Hansson, O. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0517-9 · Cited by 54 · see citing works

Discordant amyloid-β PET and CSF biomarkers and its clinical consequences

de Wilde, A., Reimand, J., Teunissen, C. E., Zwan, M. D., Windhorst, A. D., Boellaard, R., van der Flier, W. M., Scheltens, P., van Berckel, B. N. M., Bouwman, F. H., et al. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0532-x · Cited by 54 · see citing works

Harmonizing tau positron emission tomography in Alzheimer's disease: The CenTauR scale and the joint propagation model

Leuzy, A., Rakêt, L. L., Villemagne, V. L., Klein, G., Tonietto, M., Olafson, E., Baker, S. L., Saad, Z. S., Bullich, S., Lopresti, B. J., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13908 · Cited by 51 · see citing works

Association of CSF Aβ, amyloid PET, and cognition in cognitively unimpaired elderly adults

Guo, T., Shaw, L. M. J., Trojanowski, J. Q., Jagust, W. J., Landau, S. M., & Initiative, A. D. N. (2020) · Neurology · doi:10.1212/wnl.0000000000010596 · Cited by 51 · see citing works

Antemortem CSF A β 42/A β 40 ratio predicts Alzheimer's disease pathology better than A β 42 in rapidly progressive dementias

Baiardi, S., Abu‐Rumeileh, S., Rossi, M., Zenesini, C., Bartoletti‐Stella, A., Polischi, B., Capellari, S., & Parchi, P. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.697 · Cited by 53 · see citing works

Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays

Keshavan, A., Wellington, H., Chen, Z., Khatun, A., Chapman, M. D., Hart, M., Cash, D. M., Coath, W., Parker, T. D., Buchanan, S. M., et al. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12131 · Cited by 49 · see citing works

Identification of the Aβ37/42 peptide ratio in CSF as an improved Aβ biomarker for Alzheimer's disease

Liu, L., Lauro, B. M., He, A., Lee, H., Bhattarai, S., Wolfe, M. S., Bennett, D. A., Karch, C. M. M., Young‐Pearse, T. L., Dominantly Inherited Alzheimer Network (DIAN), et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12646 · Cited by 45 · see citing works

Detection of amyloid beta peptides in body fluids for the diagnosis of alzheimer’s disease: Where do we stand?

Veerabhadrappa, B., Delaby, C., Hirtz, C., Vialaret, J., Alcolea, D. A., Lleó, A., Fortea, J., Santosh, M. S., Choubey, S., & Lehmann, S. (2019) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2019.1678011 · Cited by 49 · see citing works

CSF Aβ42 and Aβ42/Aβ40 Ratio in Alzheimer’s Disease and Frontotemporal Dementias

Constantinides, V. C., Paraskevas, G. P., Boufidou, F., Bourbouli, M., Pyrgelis, E.-S., Stefanis, L., & Kapaki, E. N. (2023) · Diagnostics · doi:10.3390/diagnostics13040783 · Cited by 47 · see citing works

Amyloid-β PET—Correlation with cerebrospinal fluid biomarkers and prediction of Alzheimer´s disease diagnosis in a memory clinic

Müller, E. G., Edwin, T. H., Stokke, C., Navelsaker, S. S., Babovic, A., Bogdanović, N., Knapskog, A., & Revheim, M. E. (2019) · PLoS ONE · doi:10.1371/journal.pone.0221365 · Cited by 47 · see citing works

Assessment of the Concordance and Diagnostic Accuracy Between Elecsys and Lumipulse Fully Automated Platforms and Innotest

Dakterzada, F., Ortega, R. L., Arias, A. M., Llena, I. R., Ruiz-Julián, M., Huerto, R. P., Tahan, N., & Piñol‐Ripoll, G. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.604119 · Cited by 47 · see citing works

Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients: a multi-cohort study

Salvadó, G., Larsson, V., Cody, K. A., Cullen, N. C., Jonaitis, E. M., Stomrud, E., Kollmorgen, G., Wild, N., Palmqvist, S., Janelidze, S., et al. (2023) · Alzheimer's &amp; Dementia · doi:10.1002/alz.12907 · Cited by 46 · see citing works

Diagnostic accuracy of cerebrospinal fluid biomarkers measured by chemiluminescent enzyme immunoassay for Alzheimer disease diagnosis

Agnello, L., Piccoli, T., Vidali, M., Cuffaro, L., Sasso, B. L., Iacolino, G., Giglio, R. V., Lupo, F., Alongi, P., Bivona, G., et al. (2020) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2020.1740939 · Cited by 46 · see citing works

A Review of Application of Aβ42/40 Ratio in Diagnosis and Prognosis of Alzheimer’s Disease

Xu, C., Zhao, L., & Dong, C. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220673 · Cited by 44 · see citing works

Fully automated and highly specific plasma β-amyloid immunoassays predict β-amyloid status defined by amyloid positron emission tomography with high accuracy

Yamashita, K., Miura, M., Watanabe, S., Ishiki, K., Arimatsu, Y., Kawahira, J., Kubo, T., Sasaki, K., Arai, T., Hagino, K., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01029-0 · Cited by 43 · see citing works

Acute phase markers in CSF reveal inflammatory changes in Alzheimer’s disease that intersect with pathology, APOE ε4, sex and age

Ayton, S., Janelidze, S., Roberts, B. R., Palmqvist, S., Kalinowski, P., Diouf, I., Belaidi, A. A., Stomrud, E., Bush, A. I., & Hansson, O. (2020) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101904 · Cited by 42 · see citing works

Association Between Dietary Habits in Midlife With Dementia Incidence Over a 20-Year Period

Glans, I., Sonestedt, E., Nägga, K., Gustavsson, A.-M., González-Padilla, E., Borne, Y., Stomrud, E., Melander, O., Nilsson, P. M., Palmqvist, S., et al. (2023) · Neurology · doi:10.1212/wnl.0000000000201336 · Cited by 40 · see citing works

2023 China Alzheimer’s disease: facts and figures

Xiao, J., Li, J., Wang, J., Zhang, X., Wang, C., Peng, G., Hu, H., Liu, H., Liu, J., Shen, L., et al. (2023) · Human Brain · doi:10.37819/hb.3.1771 · Cited by 40 · see citing works

18F-Flortaucipir in TDP-43 associated frontotemporal dementia

Smith, R., Santillo, A. F., Waldö, M. L., Strandberg, O., Berron, D., Vestberg, S., van Westen, D., van Swieten, J., Honer, M., & Hansson, O. (2019) · Scientific Reports · doi:10.1038/s41598-019-42625-9 · Cited by 33 · see citing works

Diagnostic performance of a fully automated chemiluminescent enzyme immunoassay for Alzheimer's disease diagnosis

Paciotti, S., Sepe, F. N., Eusebi, P., Farotti, L., Cataldi, S., Gatticchi, L., & Parnetti, L. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.03.1612 · Cited by 26 · see citing works

Alzheimer’s cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans

Moon, S., Kim, S., Mankhong, S., Choi, S. H., Vandijck, M. L. J., Kostanjevečki, V., Jeong, J. H., Yoon, S. J., Park, K. W., Kim, E. J., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00767-3 · Cited by 28 · see citing works

Cerebrospinal fluid neurogranin/β‐site APP‐cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease

Kirsebom, B., Nordengen, K., Selnes, P., Waterloo, K. K., Torsetnes, S. B., Gísladóttir, B., Brix, B., Vanmechelen, E., Bråthen, G., Hessen, E., et al. (2018) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.10.003 · Cited by 27 · see citing works

Image reconstruction methods affect software-aided assessment of pathologies of [18F]flutemetamol and [18F]FDG brain-PET examinations in patients with neurodegenerative diseases

Lindström, E., Oddstig, J., Danfors, T., Jögi, J., Hansson, O., & Lubberink, M. (2020) · NeuroImage Clinical · doi:10.1016/j.nicl.2020.102386 · Cited by 26 · see citing works

Onset of Preclinical Alzheimer Disease in Monozygotic Twins

Konijnenberg, E., Tomassen, J., den Braber, A., ten Kate, M., Yaqub, M. M., Mulder, S. D., Nivard, M. G., Vanderstichele, H., Lammertsma, A. A., Teunissen, C. E., et al. (2021) · Annals of Neurology · doi:10.1002/ana.26048 · Cited by 25 · see citing works

Analytical and Clinical Performance of Amyloid-Beta Peptides Measurements in CSF of ADNIGO/2 Participants by an LC–MS/MS Reference Method

Korecka, M., Figurski, M., Landau, S. M., Brylska, M., Alexander, J., Blennow, K., Zetterberg, H., Jagust, W., Trojanowski, J. Q., Shaw, L. M. J., et al. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa012 · Cited by 25 · see citing works

Performance of plasma biomarkers for diagnosis and prediction of dementia in a Brazilian cohort

Santos, L. E., Mattos, P., Pinheiro, T., Silva, A., Drummond, C., Sudo, F. K., Barros‐Aragão, F. G. Q., Vanderborght, B., Brandão, C. O., Ferreira, S. T., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56756-3 · Cited by 27 · see citing works

Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays

Keshavan, A., Wellington, H., Chen, Z., Khatun, A., Chapman, M. D., Hart, M., Cash, D. M., Coath, W., Parker, T. D., Buchanan, S. M., et al. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12097 · Cited by 24 · see citing works

The Effects of Tau, Amyloid, and White Matter Lesions on Mobility, Dual Tasking, and Balance in Older People

Nilsson, M. H., Tangen, G. G., Palmqvist, S., van Westen, D., Mattsson, N., Stomrud, E., & Hansson, O. (2020) · The Journals of Gerontology Series A · doi:10.1093/gerona/glaa143 · Cited by 23 · see citing works

Microglial Activation, Tau Pathology, and Neurodegeneration Biomarkers Predict Longitudinal Cognitive Decline in Alzheimer’s Disease Continuum

Chen, Y.-H., Lin, R.-R., Huang, H.-F., Xue, Y., & Tao, Q. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.848180 · Cited by 22 · see citing works

Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease

Aichholzer, F., Klafki, H., Ogorek, I., Vogelgsang, J. S., Wiltfang, J., Scherbaum, N., Weggen, S., & Wirths, O. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00828-1 · Cited by 23 · see citing works

Treatment effects on event-related EEG potentials and oscillations in Alzheimer's disease

Yener, G., Hünerli-Gündüz, D., Yıldırım, E., Aktürk, T., Başar‐Eroğlu, C., Bonanni, L., Percio, C. D., Farina, F. R., Ferri, R., Güntekin, B., et al. (2022) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2022.05.008 · Cited by 21 · see citing works

Fluid‐based proteomics targeted on pathophysiological processes and pathologies in neurodegenerative diseases

Brinkmalm, A., Portelius, E., Brinkmalm, G., Pannee, J., Dahlén, R., Gobom, J., Blennow, K., & Zetterberg, H. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14594 · Cited by 21 · see citing works

An automated clinical mass spectrometric method for identification and quantification of variant and wild‐type amyloid‐β 1‐40 and 1‐42 peptides in CSF

DeMarco, M. L., Nguyen, Q., Fok, A., Hsiung, G. R., & van der Gugten, J. G. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12036 · Cited by 20 · see citing works

The CORCOBIA study: Cut-off points of Alzheimer’s disease CSF biomarkers in a clinical cohort

Puig‐Pijoan, A., García‐Escobar, G., Fernández‐Lebrero, A., Manero-Borràs, R. M., Sánchez‐Benavides, G., Navalpotro‐Gómez, I., Cascales‐Lahoz, D., Suárez‐Calvet, M., Grau‐Rivera, O., Boltes, A., et al. (2022) · Neurología (English Edition) · doi:10.1016/j.nrleng.2022.05.002 · Cited by 19 · see citing works

Amyloid‐β in Alzheimer's disease: Structure, toxicity, distribution, treatment, and prospects

Yu, Y., Yu, S., Battaglia, G., & Tian, X. (2024) · Ibrain · doi:10.1002/ibra.12155 · Cited by 19 · see citing works

Amyloid PET detects the deposition of brain Aβ earlier than CSF fluid biomarkers

Lowe, V. J., Mester, C. T., Lundt, E. S., Lee, J., Ghatamaneni, S., Algeciras‐Schimnich, A., Campbell, M. R., Graff‐Radford, J., Nguyen, A. T., Min, H.-K. P., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14317 · Cited by 19 · see citing works

Protein fibril length in cerebrospinal fluid is increased in Alzheimer’s disease

Nirmalraj, P. N., Schneider, T. R., Lüder, L., & Felbecker, A. (2023) · Communications Biology · doi:10.1038/s42003-023-04606-7 · Cited by 15 · see citing works

Assessment of the Correlation and Diagnostic Accuracy between Cerebrospinal Fluid and Plasma Alzheimer’s Disease Biomarkers: A Comparison of the Lumipulse and Simoa Platforms

Dakterzada, F., Cipriani, R., Ortega, R. L., Arias, A. M., Llena, I. R., Ruiz-Julián, M., Huerto, R. P., Tahan, N., Matute, C., Capetillo‐Zarate, E., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094594 · Cited by 17 · see citing works

CSF complement proteins are elevated in prodromal to moderate Alzheimer's disease patients and are not altered by the anti‐tau antibody semorinemab

Sandoval, C., Lee, J., Toth, B., Nagaraj, R., Schauer, S. P., Hoffman, J. C., Calderon, E., Kollmorgen, G., Bohorquez, S. M. S., Monteiro, C., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14271 · Cited by 18 · see citing works

Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimer’s disease

Hansson, K., Dahlén, R., Hansson, O., Pernevik, E., Paterson, R. W., Schott, J. M., Magdalinou, N. K., Zetterberg, H., Blennow, K., & Gobom, J. (2019) · Clinical mass spectrometry · doi:10.1016/j.clinms.2019.07.002 · Cited by 15 · see citing works

Dissociation of cerebrospinal fluid amyloid-β and tau levels in patients with prolonged posttraumatic disorders of consciousness

Bagnato, S., Andriolo, M., Boccagni, C., Santangelo, A., D’Ippolito, M. E., & Galardi, G. (2018) · Brain Injury · doi:10.1080/02699052.2018.1479042 · Cited by 15 · see citing works

Measurement of CSF core Alzheimer disease biomarkers for routine clinical diagnosis: do fresh vs frozen samples differ?

Bellomo, G., Cataldi, S., Paciotti, S., Paoletti, F. P., Chiasserini, D., & Parnetti, L. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00689-0 · Cited by 13 · see citing works

β-Amyloid discordance of cerebrospinal fluid and positron emission tomography imaging shows distinct spatial tau patterns

Jiang, C., Wang, Q., Xie, S., Chen, Z., Fu, L., Peng, Q., Liang, Y., Guo, H., Guo, T., & Initiative, A. D. N. (2022) · Brain Communications · doi:10.1093/braincomms/fcac084 · Cited by 14 · see citing works

Connectivity as a universal predictor of tau progression in atypical Alzheimer’s disease

de Bruin, H., Groot, C., Barthel, H., Bischof, G. N., Blazhenets, G., Boellaard, R., Boon, B. D. C., Brendel, M., Cash, D. M., Coath, W., et al. (2025) · Brain · doi:10.1093/brain/awaf279 · Cited by 11 · see citing works

Different associations between amyloid-βeta 42, amyloid-βeta 40, and amyloid-βeta 42/40 with soluble phosphorylated-tau and disease burden in Alzheimer’s disease: a cerebrospinal fluid and fluorodeoxyglucose-positron emission tomography study

Motta, C., Donna, M. G. D., Bonomi, C. G., Assogna, M., Chiaravalloti, A., Mercuri, N. B., Koch, G., & Martorana, A. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01291-w · Cited by 11 · see citing works

Biological effects of sodium phenylbutyrate and taurursodiol in Alzheimer's disease

Arnold, S. E., Hendrix, S. B., Nicodemus‐Johnson, J., Knowlton, N., Williams, V. J., Burns, J. M., Crane, M. K., McManus, A. J., Vaishnavi, S., Arvanitakis, Z., et al. (2024) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12487 · Cited by 10 · see citing works

Preclinical Alzheimer’s Disease: Implications for Refinement of the Concept

Vos, S. J. B., & Visser, P. J. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179943 · Cited by 10 · see citing works

Association of plasma β-amyloid 40 and 42 concentration with type 2 diabetes among Chinese adults

Peng, X., Xu, Z., Mo, X., Guo, Q., Yin, J., Xu, M., Peng, Z., Sun, T., Zhou, L., Peng, X., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05102-x · Cited by 9 · see citing works

How far is the goal of applying β-amyloid in cerebrospinal fluid for clinical diagnosis of Alzheimer’s disease with standardization of measurements?

Zou, Y., Yu, S., Ma, X., Ma, C., Mao, C., Mu, D., Li, L., Gao, J., & Qiu, L. (2022) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2022.11.013 · Cited by 9 · see citing works

Contribution of clinical information to the predictive performance of plasma β-amyloid levels for amyloid positron emission tomography positivity

Chun, M. Y., Jang, H., Kim, H. J., Kim, J. P., Gallacher, J., Allué, J. A., Sarasa, L., Castillo, S., Pascual‐Lucas, M., Na, D. L., et al. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1126799 · Cited by 9 · see citing works

Dementia Prevention Research Clinic: a longitudinal study investigating factors influencing the development of Alzheimer's disease in Aotearoa, New Zealand

Tippett, L. J., Cawston, E. E., Morgan, C., Melzer, T. R., Brickell, K. L., Ilse, C., Cheung, G., Kirk, I. J., Roberts, R. P., Govender, J., et al. (2022) · Journal of the Royal Society of New Zealand · doi:10.1080/03036758.2022.2098780 · Cited by 8 · see citing works

Connecting Cohorts to Diminish Alzheimer’s Disease (CONCORD-AD): A Report of an International Research Collaboration Network

Pavlik, V. N., for the CONCORD-AD investigators, Burnham, S. C., Kass, J. S., Helmer, C., Palmqvist, S., Vassilaki, M., Dartigues, J., Hansson, O., Masters, C. L., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210525 · Cited by 8 · see citing works

Use of Alzheimer’s Disease Cerebrospinal Fluid Biomarkers in A Tertiary Care Memory Clinic

Stiffel, M., Bergeron, D., Amari, K. M., Poulin, É., Roberge, X., Meilleur‐Durand, S., Sellami, L., Molin, P., Nadeau, Y., Fortin, M., et al. (2021) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2021.67 · Cited by 8 · see citing works

Cholinesterase inhibitor use in amyloid PET-negative mild cognitive impairment and cognitive changes

Pyun, J., Park, Y. H., Kang, M. J., & Kim, S. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01580-y · Cited by 6 · see citing works

Estudio CORCOBIA: determinación de puntos de corte de biomarcadores de enfermedad de Alzheimer en LCR en una cohorte clínica

Puig‐Pijoan, A., García‐Escobar, G., Fernández‐Lebrero, A., Borràs, R. M. M., Sánchez‐Benavides, G., Navalpotro‐Gómez, I., Cascales‐Lahoz, D., Suárez‐Calvet, M., Grau‐Rivera, O., Boltes, A., et al. (2022) · Neurología · doi:10.1016/j.nrl.2022.05.005 · Cited by 6 · see citing works

Blood‐based biomarkers for Alzheimer's disease and related dementias: Keys to success and things to consider

Zetterberg, H., Apostolova, L. G., & Snyder, P. J. (2019) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.10.001 · Cited by 6 · see citing works

Operationalizing selection criteria for clinical trials in Alzheimer's disease: Biomarker and clinical considerations

Petersen, R. C., Graf, A., Brady, C., Santi, S. D., Florian, H., Landen, J. W., Pontecorvo, M., RANDOLPH, C. C., Sink, K. M., Carrillo, M. C., et al. (2023) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12434 · Cited by 4 · see citing works

Characteristics of discordance between amyloid positron emission tomography and plasma amyloid-β 42/40 positivity

Pyun, J., Park, Y. H., Youn, Y. C., Kang, M. J., Shim, K. H., Jang, J., You, J., Nho, K. T., Kim, S., Initiative, T. A. D. N., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02766-6 · Cited by 7 · see citing works

Reference measurement procedure for CSF amyloid beta (Aβ)1–42 and the CSF Aβ1–42/Aβ1–40 ratio – a cross‐validation study against amyloid PET

Pannee, J., Portelius, E., Minthon, L., Gobom, J., Andréasson, U., Zetterberg, H., Hansson, O., & Blennow, K. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13838 · Cited by 84 · see citing works

Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging

Doecke, J. D., Ward, L. D., Burnham, S. C., Villemagne, V. L., Li, Q.-X., Collins, S. J., Fowler, C. J., Manuilova, E., Widmann, M., Rainey‐Smith, S. R., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00595-5 · Cited by 79 · see citing works

Concordance between the updated Elecsys cerebrospinal fluid immunoassays and amyloid positron emission tomography for Alzheimer’s disease assessment: findings from the Apollo study

Schinke, H., Jonsson, M. F., Gummesson, M., Nilsson, R., Gaupp, S., Manuilova, E., McIlwrick, S., Weinberger, J.-P., Rutz, S., Carboni, M., et al. (2025) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2024-1476 · Cited by 2 · see citing works

Pittsburgh compound B imaging and cerebrospinal fluid amyloid-β in a multicentre European memory clinic study

Leuzy, A., Chiotis, K., Hasselbalch, S. G., Rinne, J. O., de Mendonça, A., Otto, M., Lleó, A., Castelo-Branco, M. S., Santana, I. J., Johansson, J. J., et al. (2016) · Brain · doi:10.1093/brain/aww160 · Cited by 132 · see citing works

O4‐11‐05: The correlation between ß‐amyloid PET‐imaging and cerebrospinal fluid biomarkers is affected by the assay design

Rembach, A., Vanderstichele, H., Li, Q.-X., Varghese, S., Sarros, S., Fowler, C. J., Masters, C. L., Collins, S. J., Stoops, E., Herbst, V., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.07.409